Suppr超能文献

牛磺罗定作为腹膜透析患者复发性腹膜炎的辅助治疗。

Taurolidine as adjuvant treatment of relapsing peritonitis in peritoneal dialysis patients.

机构信息

Servicio de Nefrología, Hospital Universitario Virgen Macarena, Sevilla, España.

Servicio de Nefrología, Hospital Universitario Virgen Macarena, Sevilla, España.

出版信息

Nefrologia (Engl Ed). 2020 Mar-Apr;40(2):197-201. doi: 10.1016/j.nefro.2019.03.014. Epub 2019 Jun 15.

Abstract

Relapsing peritonitis in peritoneal dialysis patients is one of the complications that jeopardizes the continuity of the technique. It is often associated with the formation of biofilm in the lumen of the catheter. To date, its removal remains the only recommended attitude. Due to its antimicrobial and antifungal properties, taurolidine has been previously used for the sealing of central line catheters and hemodialysis. Despite the good results obtained, there is no evidence available regarding its utility in peritoneal dialysis. This case report describes the use of taurolidine (TauroLock™HEP500) in 5 patients with relapsing peritonitis after antibiotic treatment completion. Mean follow-up for the detection of recurrences was 13.4 months. In 4 patients with infections caused by Staphylococcus epidermidis, eradication was achieved. In the remaining case, caused by Staphylococcus aureus, the taurolidine seal was ineffective and the removal of the catheter was required.

摘要

腹膜透析患者复发性腹膜炎是危及该技术连续性的并发症之一。它通常与导管管腔中生物膜的形成有关。迄今为止,其清除仍然是唯一推荐的方法。由于牛磺罗定具有抗菌和抗真菌特性,因此先前曾用于中央导管和血液透析的密封。尽管取得了良好的效果,但尚无关于其在腹膜透析中应用的证据。本病例报告描述了在完成抗生素治疗后,有 5 例复发性腹膜炎患者使用牛磺罗定(TauroLock™HEP500)。为了检测复发,平均随访时间为 13.4 个月。在 4 例由表皮葡萄球菌引起的感染中,均达到了清除效果。在剩余的由金黄色葡萄球菌引起的病例中,牛磺罗定密封无效,需要取出导管。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验